Ligands to the melanocortin receptors
- 1 October 2001
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 11 (10) , 1583-1592
- https://doi.org/10.1517/13543776.11.10.1583
Abstract
This review will give a brief overview of the pharmacology of the melanocortin receptors (MCRs) as a background. The review will not handle the patents or patent applications dealing with cloning of the different subtypes of the receptor, since this has been recently reviewed [1]. This review will focus on different ligands acting either as agonists or antagonists to the different subtypes of the receptor, i.e., MC1R, MC3R, MC4R and MC5R. Just recently a number of patent applications have reached the public domain, which describe small peptides or low molecular weight organic compounds binding and acting on the MCRs.Keywords
This publication has 43 references indexed in Scilit:
- Melanocortin receptors: new opportunities in drug discoveryExpert Opinion on Therapeutic Patents, 2001
- Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonistBritish Journal of Pharmacology, 1999
- Selective Antagonist for the Melanocortin 4 Receptor (HS014) Increases Food Intake in Free-Feeding RatsBiochemical and Biophysical Research Communications, 1998
- Obesity Sheds Its SecretsScience, 1997
- Localization of ACTH receptor mRNA by in situ hybridization in mouse adrenal glandCell and tissue research, 1996
- The Neuropeptide Alpha-Melanocyte-Stimulating Hormone Inhibits Experimental Arthritis in RatsNeuroimmunomodulation, 1994
- Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNAFEBS Letters, 1992
- Neuropeptide α-MSH antagonizes IL-6- and TNF-induced feverPeptides, 1991
- Alpha-MSH peptides inhibit acute inflammation and contact sensitivityPeptides, 1990
- Antipyretic Potency of Centrally Administered α-Melanocyte Stimulating HormoneScience, 1983